Drug intelligence / Profile preview

[177Lu]Lu-3BP-3940

Development stage
Preclinical
Lead developer
3B Pharmaceuticals
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Peptides
Administration
Intravesical, Intravenous
01

Overview

[177Lu]Lu-3BP-3940 is an investigational lutetium-177-labeled radiopharmaceutical developed by 3B Pharmaceuticals [1.2.5]. It consists of the cyclic peptide 3BP-3940, which is a structural variant of FAP-2286 designed with modifications to reduce renal uptake and retention, conjugated to a DOTA chelator and labeled with the beta-emitting radioisotope lutetium-177. The drug specifically targets fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors. By binding to FAP, [177Lu]Lu-3BP-3940 delivers localized cytotoxic beta radiation directly to FAP-expressing tumors and their stroma [1.2.5]. It has been evaluated in preclinical models and used on a named-patient basis / investigator-initiated trials in patients with advanced metastatic solid tumors (such as pancreatic adenocarcinoma, breast cancer, lung cancer, and sarcomas) and high-grade muscle-invasive bladder cancer.

Other names
3BP-3940lutetium (177Lu) 3BP-3940lutetium-177-labeled 3BP-3940lutetium177-labeled 3BP-3940lutetium 177-labeled 3BP-3940
02

Identity

Drug type
Peptides
Modality
PeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma Emitters
Synonyms and codes
177Lu-3BP-3940
03

Pharmacology

Route
IntravesicalIntravenous
04

Development

IndicationHighest phaseStatus
colorectal cancer (CRC) and precursor lesionsPreclinicalActive
lung cancer and precursor lesionsPreclinicalActive
metastatic breast cancer (mBC)PreclinicalActive
muscle-invasive bladder cancer (MIBC)PreclinicalActive
pancreatic ductal adenocarcinoma (PDAC)PreclinicalActive
soft-tissue sarcomasPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Competitive landscape

Drugs on the same target
95
Drugs in the lead indication
1,201

Lead indication: colorectal cancer (CRC) and precursor lesions

Most advanced in the lead indication

  1. afliberceptApproved
  2. bevacizumabApproved
  3. capecitabineApproved
  4. folinic acidApproved
  5. fruquintinibApproved

Beyond the preview

Go deeper on [177Lu]Lu-3BP-3940.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [177Lu]Lu-3BP-3940.

Work on [177Lu]Lu-3BP-3940? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call